Ian Coyle-Gilchrist
Overview
Explore the profile of Ian Coyle-Gilchrist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
498
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Whiteside D, Street D, Murley A, Jones P, Malpetti M, Ghosh B, et al.
Hum Brain Mapp
. 2023 Jun;
44(11):4239-4255.
PMID: 37269181
There is a pressing need to understand the factors that predict prognosis in progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), with high heterogeneity over the poor average survival. We...
2.
Enwo O, Ibrahim D, Boughton M, Coyle-Gilchrist I
BMJ Case Rep
. 2023 Jan;
16(1).
PMID: 36717159
The varicella zoster virus (VZV) is a ubiquitous, neurotropic pathogen capable of reactivation from sensory ganglion cells to cause dermatomal herpes zoster infection, alongside a range of pathologies within the...
3.
Whiteside D, Malpetti M, Jones P, Ghosh B, Coyle-Gilchrist I, Van Swieten J, et al.
Alzheimers Dement
. 2022 Nov;
19(5):1947-1962.
PMID: 36377606
Introduction: We tested whether changes in functional networks predict cognitive decline and conversion from the presymptomatic prodrome to symptomatic disease in familial frontotemporal dementia (FTD). Methods: For hypothesis generation, 36...
4.
Stoker T, Dostal V, Cochius J, Williams-Gray C, Scherzer C, Wang J, et al.
J Neurol
. 2022 Jul;
269(12):6667-6672.
PMID: 35895135
No abstract available.
5.
Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants
Street D, Malpetti M, Rittman T, Ghosh B, Murley A, Coyle-Gilchrist I, et al.
Brain Commun
. 2021 Sep;
3(3):fcab206.
PMID: 34541533
Progressive supranuclear palsy causes diverse clinical presentations, including classical Richardson's syndrome and several variant phenotypes. Clinical trials of disease-modifying therapies have recently been completed, with more planned for the next...
6.
Whiteside D, Jones P, Ghosh B, Coyle-Gilchrist I, Gerhard A, Hu M, et al.
Neurobiol Aging
. 2021 Aug;
107:109-117.
PMID: 34419788
The clinical syndromes of Progressive Supranuclear Palsy (PSP) may be mediated by abnormal temporal dynamics of brain networks, due to the impact of atrophy, synapse loss and neurotransmitter deficits. We...
7.
Murley A, Coyle-Gilchrist I, Rouse M, Jones P, Li W, Wiggins J, et al.
Brain
. 2020 May;
143(5):1555-1571.
PMID: 32438414
The syndromes caused by frontotemporal lobar degeneration have highly heterogeneous and overlapping clinical features. There has been great progress in the refinement of clinical diagnostic criteria in the past decade,...
8.
Shaw A, Hughes L, Moran R, Coyle-Gilchrist I, Rittman T, Rowe J
Cereb Cortex
. 2019 Jun;
31(3):1837-1847.
PMID: 31216360
The analysis of neural circuits can provide crucial insights into the mechanisms of neurodegeneration and dementias, and offer potential quantitative biological tools to assess novel therapeutics. Here we use behavioral...
9.
Rae C, Nombela C, Vazquez Rodriguez P, Ye Z, Hughes L, Jones P, et al.
Brain
. 2016 Jun;
139(Pt 8):2235-48.
PMID: 27343257
Parkinson's disease impairs the inhibition of responses, and whilst impulsivity is mild for some patients, severe impulse control disorders affect ∼10% of cases. Based on preclinical models we proposed that...
10.
Ye Z, Rae C, Nombela C, Ham T, Rittman T, Jones P, et al.
Hum Brain Mapp
. 2016 Jan;
37(3):1026-37.
PMID: 26757216
Recent studies indicate that selective noradrenergic (atomoxetine) and serotonergic (citalopram) reuptake inhibitors may improve response inhibition in selected patients with Parkinson's disease, restoring behavioral performance and brain activity. We reassessed...